For those who are interested in a deeper dive on this technology, its potential limitations, and its potential benefits, I wrote up a three-part series earlier this year breaking down recent advances in liquid-biopsy-based cancer detection:
Part I: regarding tumor fraction (this goes into depth about the stage I limitations noted by other commenters) https://ihaque.org/posts/2019/07/02/early-detection-mid-2019...
Part II: technical advances from Grail (the authors here) and Guardant (one of their main commercial competitors) https://ihaque.org/posts/2019/07/08/early-detection-mid-2019...
Part III: clinical performance and economics - integrating the sensitivity and specificity numbers with a simple model for important clinical parameters like adherence (how many people prescribed to take the test actually do), and cost: https://ihaque.org/posts/2019/08/18/early-detection-mid-2019...
Disclaimer: I'm the former CSO of a competing company, but I no longer work in this space.